Prohost Portfolio PLUS #3
We were looking forward to learning more important details about the German firm, CureVac N.V. (CVAC), when the company announced business updates and financial results for its fourth quarter and full-year 2020. The reason for our interest was the fact that the U.S. was looking to take over this firm two years ago to no avail. A more important reason was that its products and vaccines are based on the mRNA creation and usage – the same technology that helped to create the COVID-19 vaccines . . .
This content is for paid subscribers.
Prohost Letters April 18, 2021